相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A novel near-infrared fluorescence off-on probe for imaging hypoxia and nitroreductase in cells and in vivo
Yu Zhang et al.
SENSORS AND ACTUATORS B-CHEMICAL (2022)
Detection of Hypoxia in Cancer Models: Significance, Challenges, and Advances
Ines Godet et al.
CELLS (2022)
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin
Luke S. McLean et al.
INVESTIGATIONAL NEW DRUGS (2022)
Nitro-Pyrazinotriazapentalene scaffolds- nitroreductase quantification and in vitro fluorescence imaging of hypoxia
Ewelina Janczy-Cempa et al.
SENSORS AND ACTUATORS B-CHEMICAL (2021)
NAD(P)H Quinone Oxidoreductase-1 in Organ and Tumor Tissues: Distinct Activity Levels Observed with a Benzo-rosol-Based Dual-Excitation and Dual-Emission Probe
Yun Jae Yang et al.
ANALYTICAL CHEMISTRY (2021)
Targeting Hypoxia: Revival of Old Remedies
Nuria Vilaplana-Lopera et al.
BIOMOLECULES (2021)
Roles of NAD(P)H:quinone Oxidoreductase 1 in Diverse Diseases
Wang-Soo Lee et al.
LIFE-BASEL (2021)
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Vittoria Infantino et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Small-molecule probes for fluorescent detection of cellular hypoxia-related nitroreductase
Jian Qiao et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2021)
Flavylium-Based Hypoxia-Responsive Probe for Cancer Cell Imaging
Thitima Pewklang et al.
MOLECULES (2021)
Therapeutic targeting of the hypoxic tumour microenvironment
Dean C. Singleton et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Engineering the Escherichia coli Nitroreductase NfsA to Create a Flexible Enzyme-Prodrug Activation System
Abigail Sharrock et al.
FRONTIERS IN PHARMACOLOGY (2021)
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
Yue Li et al.
FRONTIERS IN ONCOLOGY (2021)
Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models
Fokko J. Huizing et al.
PHYSICS & IMAGING IN RADIATION ONCOLOGY (2021)
A NIR fluorescent smart probe for imaging tumor hypoxia
Kenneth S. Hettie et al.
CANCER REPORTS (2021)
Design strategy of optical probes for tumor hypoxia imaging
Fengfeng Xue et al.
SCIENCE CHINA-LIFE SCIENCES (2020)
Recent progress in the design principles, sensing mechanisms, and applications of small-molecule probes for nitroreductases
Ya-Lin Qi et al.
COORDINATION CHEMISTRY REVIEWS (2020)
The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond
Silvia Pastorekova et al.
CANCER AND METASTASIS REVIEWS (2019)
Characterization of a highly specific NQO1-activated near- infrared fluorescent probe and its application for in vivo tumor imaging
Surendra Reddy Punganuru et al.
SCIENTIFIC REPORTS (2019)
Azoreductase-Responsive Nanoprobe for Hypoxia-Induced Mitophagy Imaging
Dandan Ma et al.
ANALYTICAL CHEMISTRY (2019)
NBGNU: a hypoxia-activated tripartite combi-nitrosourea prodrug overcoming AGT-mediated chemoresistance
Yao Ge et al.
FUTURE MEDICINAL CHEMISTRY (2019)
Reductive Activity and Mechanism of Hypoxia-Targeted AGT Inhibitors: An Experimental and Theoretical Investigation
Weinan Xiao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
Linda Spiegelberg et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2019)
Insights into Hypoxia: Non-invasive Assessment through Imaging Modalities and Its Application in Breast Cancer
Isaac Daimiel
JOURNAL OF BREAST CANCER (2019)
Novel designed azo substituted semi-cyanine fluorescent probe for cytochrome P450 reductase detection and hypoxia imaging in cancer cells
Caiyue Wang et al.
RSC ADVANCES (2019)
Clinical trials targeting hypoxia
Hannah Tharmalingham et al.
BRITISH JOURNAL OF RADIOLOGY (2018)
Regulatory mechanisms of hypoxia-inducible factor 1 activity: Two decades of knowledge
Sho Koyasu et al.
CANCER SCIENCE (2018)
Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides
Muriel Bonnet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Azoreductase: a key player of xenobiotic metabolism
Santosh A. Misal et al.
BIORESOURCES AND BIOPROCESSING (2018)
Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome
Jae-Young Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy
Ishna N. Mistry et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
Katarzyna J. Nytko et al.
ONCOTARGET (2017)
A Probe for the Detection of Hypoxic Cancer Cells
Shenzheng Luo et al.
ACS SENSORS (2017)
Bioluminescent Probe for Tumor Hypoxia Detection via CYP450 Reductase in Living Animals
Yuqi Gao et al.
ANALYTICAL CHEMISTRY (2017)
Molecular mechanisms of hypoxia in cancer
Amarnath Challapalli et al.
CLINICAL AND TRANSLATIONAL IMAGING (2017)
Chemical Design and Synthesis of Functionalized Probes for Imaging and Treating Tumor Hypoxia
Jia-nan Liu et al.
CHEMICAL REVIEWS (2017)
Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy
Janine N. Copp et al.
CELL CHEMICAL BIOLOGY (2017)
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
Ruben T. H. M. Larue et al.
BMC CANCER (2016)
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
Francis W. Hunter et al.
BRITISH JOURNAL OF CANCER (2016)
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Roger M. Phillips
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects
Maria Giulia Battelli et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2016)
A water-soluble conjugated polymer with azobenzol side chains based on turn-on effect for hypoxic cell imaging
Jie Li et al.
POLYMER CHEMISTRY (2016)
Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility
Elsie M. Williams et al.
BIOCHEMICAL JOURNAL (2015)
in vivo imaging and detection of nitroreductase in zebrafish by a new near-infrared fluorescence off-on probe
Zhao Li et al.
BIOSENSORS & BIOELECTRONICS (2015)
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs
Francis W. Hunter et al.
CANCER RESEARCH (2015)
TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Sarah G. J. A. Peeters et al.
CLINICAL CANCER RESEARCH (2015)
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Mitesh J. Borad et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ultrasensitive Near-Infrared Fluorescence-Enhanced Probe for in Vivo Nitroreductase Imaging
Yuhao Li et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma
Mohamed A. Hassan Metwally et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Optimizing Hypoxia Detection and Treatment Strategies
Cameron J. Koch et al.
SEMINARS IN NUCLEAR MEDICINE (2015)
The Clinical Significance of Hypoxia in Human Cancers
Neesha Dhani et al.
SEMINARS IN NUCLEAR MEDICINE (2015)
Xanthine Oxidase: Isolation, Assays of Activity, and Inhibition
Danijela A. Kostic et al.
JOURNAL OF CHEMISTRY (2015)
HIF-1α pathway: role, regulation and intervention for cancer therapy
Georgina N. Masoud et al.
ACTA PHARMACEUTICA SINICA B (2015)
Imaging tumour hypoxia with positron emission tomography
I. N. Fleming et al.
BRITISH JOURNAL OF CANCER (2015)
Application of Electron Paramagnetic Resonance (EPR) Oximetry to Monitor Oxygen in Wounds in Diabetic Models
Celine M. Desmet et al.
PLOS ONE (2015)
The Clinical Importance of Assessing Tumor Hypoxia: Relationship of Tumor Hypoxia to Prognosis and Therapeutic Opportunities
Joseph C. Walsh et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5
Jingli Wang et al.
BIOCHEMICAL PHARMACOLOGY (2014)
The Mononuclear Molybdenum Enzymes
Russ Hille et al.
CHEMICAL REVIEWS (2014)
Recent progress in the development of near-infrared fluorescent probes for bioimaging applications
Zhiqian Guo et al.
CHEMICAL SOCIETY REVIEWS (2014)
NIMRAD - A Phase III Trial to Investigate the Use of Nimorazole Hypoxia Modification with Intensity-modulated Radiotherapy in Head and Neck Cancer
D. Thomson et al.
CLINICAL ONCOLOGY (2014)
Transcriptional regulation by hypoxia inducible factors
Veronica L. Dengler et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2014)
Human cytochrome b5 reductase: structure, function, and potential applications
Fatemeh Elahian et al.
CRITICAL REVIEWS IN BIOTECHNOLOGY (2014)
Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
Sant P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Development of Azo-Based Fluorescent Probes to Detect Different Levels of Hypoxia
Wen Piao et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
Design, synthesis and ex vivo evaluation of colon-specific azo based prodrugs of anticancer agents
Rajiv Sharma et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Enzymatic Conversion of 6-Nitroquinoline to the Fluorophore 6-Aminoquinoline Selectively under Hypoxic Conditions
Anuruddha Rajapakse et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2013)
NADPH P450 oxidoreductase: Structure, function, and pathology of diseases
Amit V. Pandey et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Impact of Tumor Blood Flow Modulation on Tumor Sensitivity to the Bioreductive Drug Banoxantrone
Eugene Manley et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
Mark J. McKeage et al.
BMC CANCER (2012)
Hypoxia-Inducible Factors in Physiology and Medicine
Gregg L. Semenza
CELL (2012)
A Strategy for Selective O6-Alkylguanine-DNA Alkyltransferase Depletion Under Hypoxic Conditions
Philip G. Penketh et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2012)
The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia
Jingli Wang et al.
CLINICAL CANCER RESEARCH (2012)
PET of Hypoxia: Current and Future Perspectives
Sean Carlin et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Passing the baton: the HIF switch
Mei Yee Koh et al.
TRENDS IN BIOCHEMICAL SCIENCES (2012)
Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia
Christopher P. Guise et al.
MOLECULAR PHARMACOLOGY (2012)
Hypoxia. 2. Hypoxia regulates cellular metabolism
William W. Wheaton et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2011)
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
Glen J. Weiss et al.
CLINICAL CANCER RESEARCH (2011)
ACUTE VERSUS CHRONIC HYPOXIA: WHY A SIMPLIFIED CLASSIFICATION IS SIMPLY NOT ENOUGH
Christine Bayer et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
4-Nitrobenzyloxycarbonyl Derivatives of O6-Benzylguanine as Hypoxia-Activated Prodrug Inhibitors of O6-Alkylguanine-DNA Alkyltransferase (AGT), Which Produces Resistance to Agents Targeting the O-6 Position of DNA Guanine
Rui Zhu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Synthesis of Mutual Azo Prodrugs of Anti-inflammatory Agents and Peptides Facilitated by α-Aminoisobutyric Acid
David A. Kennedy et al.
JOURNAL OF ORGANIC CHEMISTRY (2011)
Oxygen Sensing, Homeostasis, and Disease
David De Bels et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
Kristen N. Ganjoo et al.
ONCOLOGY (2011)
Xanthine Oxidase Inhibition Attenuates Endothelial Dysfunction Caused by Chronic Intermittent Hypoxia in Rats
John M. Dopp et al.
RESPIRATION (2011)
Activation of nitrofurazone by azoreductases: multiple activities in one enzyme
Ali Ryan et al.
SCIENTIFIC REPORTS (2011)
Targeting hypoxia in cancer therapy
William R. Wilson et al.
NATURE REVIEWS CANCER (2011)
MECHANISMS OF DISEASE Oxygen Sensing, Homeostasis, and Disease
Gregg L. Semenza
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders
David M. Goldstein et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode
Lise Sakso Mortensen et al.
ACTA ONCOLOGICA (2010)
Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors
Kevin O. Hicks et al.
CLINICAL CANCER RESEARCH (2010)
Hydrogen peroxide is the major oxidant product of xanthine oxidase
Eric E. Kelley et al.
FREE RADICAL BIOLOGY AND MEDICINE (2010)
Substrate Orientation and Catalytic Specificity in the Action of Xanthine Oxidase THE SEQUENTIAL HYDROXYLATION OF HYPOXANTHINE TO URIC ACID
Hongnan Cao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis
Adrian M. Jubb et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Hypoxia-Sensitive Fluorescent Probes for in Vivo Real-Time Fluorescence Imaging of Acute Ischemia
Kazuki Kiyose et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
HIF-1 and HIF-2 transcription factors - Similar but not identical
Agnieszka Loboda et al.
MOLECULES AND CELLS (2010)
Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET
Romain Bejot et al.
NUCLEAR MEDICINE AND BIOLOGY (2010)
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
G. L. Semenza
ONCOGENE (2010)
Characterization of a Nitroreductase with Selective Nitroreduction Properties in the Food and Intestinal Lactic Acid Bacterium Lactobacillus plantarum WCFS1
Hugo Guillen et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2009)
Design and identification of the novel hypoxia-activated irreversible pan-HER inhibitor SN29966
Jeff B. Smaill et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Clinical biomarkers for hypoxia targeting
Quynh-Thu Le et al.
CANCER AND METASTASIS REVIEWS (2008)
Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase
Tomoko Nishino et al.
FEBS JOURNAL (2008)
A Dialogue between the Hypoxia-Inducible Factor and the Tumor Microenvironment
Frederic Dayan et al.
CANCER MICROENVIRONMENT (2008)
Hypoxia and cancer
M. Christiane Brahimi-Horn et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Methods for noninvasive imaging of tissue hypoxia
Deepti S. Vikram et al.
ANTIOXIDANTS & REDOX SIGNALING (2007)
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A:: A role for NADPH:cytochrome P450 oxidoreductase under hypoxia
Chris P. Guise et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy
Xiao-Feng Li et al.
CANCER RESEARCH (2007)
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study
W. P. Steward et al.
ANNALS OF ONCOLOGY (2007)
Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment
Benjamin J. Moeller et al.
CANCER AND METASTASIS REVIEWS (2007)
Review: Implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions
An Wouters et al.
ONCOLOGIST (2007)
Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas
QT Le et al.
CANCER (2006)
Moderate hypoxia induces xanthine oxidoreductase activity in arterial endothelial cells
EE Kelley et al.
FREE RADICAL BIOLOGY AND MEDICINE (2006)
QSAR and SAR studies on the reduction of some aromatic nitro compounds by xanthine oxidase
M Thakur et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2006)
Binding of the anticancer prodrug CB1954 to the activating enzyme NQO2 revealed by the crystal structure of their complex
M AbuKhader et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial
J Overgaard et al.
LANCET ONCOLOGY (2005)
The HIF pathway in cancer
PH Maxwell
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2005)
1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: An anticancer agent targeting hypoxic cells
HA Seow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02)
D Rischin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: Final results of a randomized clinical trial
BG Haffty et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response
P Vaupel et al.
ONCOLOGIST (2004)
Posttranslational inactivation of human xanthine oxidoreductase by oxygen under standard cell culture conditions
N Linder et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2003)
Prognostic significance of tumor oxygenation in humans
SM Evans et al.
CANCER LETTERS (2003)
Xanthine oxidase-catalyzed metabolism of 2-nitrofluorene, a carcinogenic air pollutant, in rat skin
O Ueda et al.
DRUG METABOLISM AND DISPOSITION (2003)
Nuclear overexpression of NADH:cytochrome b5 reductase activity increases the cytotoxicity of mitomycin C (MC) and the total number of MC-DNA adducts in Chinese hamster ovary cells
KM Holtz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Structures of nitroreductase in three states - Effects of inhibitor binding and reduction
CA Haynes et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species
SM Bailey et al.
BIOCHEMICAL PHARMACOLOGY (2001)
Phosphorylation of xanthine dehydrogenase/oxidase in hypoxia
US Kayyali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia induced radiation resistance rather than hypoxia-induced metastasis
EK Rofstad et al.
BRITISH JOURNAL OF CANCER (2000)
Role of NADPH : Cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia
T Melo et al.
BIOCHEMICAL PHARMACOLOGY (2000)
分享论文
